HUP9901359A3 - Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them - Google Patents

Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them

Info

Publication number
HUP9901359A3
HUP9901359A3 HU9901359A HUP9901359A HUP9901359A3 HU P9901359 A3 HUP9901359 A3 HU P9901359A3 HU 9901359 A HU9901359 A HU 9901359A HU P9901359 A HUP9901359 A HU P9901359A HU P9901359 A3 HUP9901359 A3 HU P9901359A3
Authority
HU
Hungary
Prior art keywords
atherosclerosis
producing
treatment
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU9901359A
Other languages
Hungarian (hu)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608646.7A external-priority patent/GB9608646D0/en
Priority claimed from GBGB9623756.5A external-priority patent/GB9623756D0/en
Priority claimed from GBGB9625121.0A external-priority patent/GB9625121D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of HUP9901359A2 publication Critical patent/HUP9901359A2/en
Publication of HUP9901359A3 publication Critical patent/HUP9901359A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9901359A 1996-04-26 1997-04-15 Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them HUP9901359A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9608646.7A GB9608646D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9623756.5A GB9623756D0 (en) 1996-11-15 1996-11-15 Novel compounds
GBGB9625121.0A GB9625121D0 (en) 1996-12-03 1996-12-03 Novel compounds

Publications (2)

Publication Number Publication Date
HUP9901359A2 HUP9901359A2 (en) 1999-08-30
HUP9901359A3 true HUP9901359A3 (en) 2000-03-28

Family

ID=27268259

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901359A HUP9901359A3 (en) 1996-04-26 1997-04-15 Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them

Country Status (17)

Country Link
EP (1) EP0915843A1 (en)
JP (1) JP2000509049A (en)
AR (1) AR006833A1 (en)
AU (1) AU2698697A (en)
BR (1) BR9709196A (en)
CA (1) CA2252696A1 (en)
CZ (1) CZ341098A3 (en)
HU (1) HUP9901359A3 (en)
ID (1) ID16660A (en)
IL (1) IL126696A0 (en)
MA (1) MA26426A1 (en)
NO (1) NO984939L (en)
NZ (1) NZ332476A (en)
PE (1) PE64398A1 (en)
PL (1) PL329530A1 (en)
TR (1) TR199802160T2 (en)
WO (1) WO1997041098A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001235466B2 (en) 2000-02-16 2004-04-22 Glaxo Group Limited Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors
WO2002079174A2 (en) 2001-03-28 2002-10-10 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
DE60216275T2 (en) * 2001-05-25 2007-06-21 Schering Corp. USE OF AZETIDINONE-SUBSTITUTED DERIVATIVES IN THE TREATMENT OF ALZHEIMER DISEASE
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
KR101730290B1 (en) 2007-05-11 2017-04-25 토마스 제퍼슨 유니버시티 Methods of treatment and prevention of neurodegenerative diseases and disorders
CA2687079A1 (en) 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
EP2649053B1 (en) 2010-12-06 2015-11-04 Glaxo Group Limited Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp-pla2
US20130267544A1 (en) 2010-12-17 2013-10-10 Peter Adamson Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
EP2725024A4 (en) 2011-06-27 2014-12-03 Shanghai Inst Materia Medica Azole heterocyclic compound, preparation method, pharmaceutical composition and use
US9273054B2 (en) 2011-07-27 2016-03-01 Glaxo Group Limited Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors
EP2739627A4 (en) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one compounds use as lp-pla² inhibitors
UY35276A (en) 2013-01-25 2014-08-29 Glaxosmithkline Ip Dev Ltd New compounds that inhibit the activity of Lp-PLA2
RU2015135806A (en) 2013-01-25 2017-03-03 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед COMPOUNDS
KR20150108896A (en) 2013-01-25 2015-09-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Bicyclic pyrimidone compounds as inhibitors of lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
PE20230092A1 (en) 2019-11-09 2023-01-16 Shanghai Simr Biotechnology Co Ltd DIHYDROIMIDAZOPYRIMIDONE TRICYCLIC DERIVATIVE, METHOD OF PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CN115304620A (en) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
CZ14294A3 (en) * 1991-07-23 1994-07-13 Schering Corp Substituted beta-lactam compounds usable as hypocholesterol pharmaceutical preparations and process for preparing thereof
CA2108584C (en) * 1992-10-27 1998-11-24 James B. Doherty Substituted azetidinones as anti-inflammatory and antidegenerative agents
AU5802894A (en) * 1992-12-17 1994-07-04 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5981252A (en) * 1993-06-25 1999-11-09 Smithkline Beecham Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy
PT673426E (en) * 1993-10-06 2001-11-30 Icos Corp ACETYL HYDROLASE OF THE ACTIVATING FACTOR OF PLATELETS
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
AP9701007A0 (en) * 1994-12-22 1997-07-31 Smithkline Beecham Plc Substituted azetidin-2-ones for treatment of atherosclerosis.
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
CA2225627A1 (en) * 1995-07-01 1997-01-23 Deirdre Mary Bernadette Hickey Azetidinone derivatives for the treatment of atherosclerosis
JP2000505063A (en) * 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Azetidinone compounds for the treatment of atherosclerosis

Also Published As

Publication number Publication date
TR199802160T2 (en) 1999-04-21
ID16660A (en) 1997-10-30
NO984939D0 (en) 1998-10-23
PL329530A1 (en) 1999-03-29
CA2252696A1 (en) 1997-11-06
EP0915843A1 (en) 1999-05-19
NO984939L (en) 1998-12-23
HUP9901359A2 (en) 1999-08-30
PE64398A1 (en) 1999-01-06
WO1997041098A1 (en) 1997-11-06
AU2698697A (en) 1997-11-19
IL126696A0 (en) 1999-08-17
MA26426A1 (en) 2004-12-20
NZ332476A (en) 2000-06-23
CZ341098A3 (en) 1999-03-17
JP2000509049A (en) 2000-07-18
AR006833A1 (en) 1999-09-29
BR9709196A (en) 1999-05-25

Similar Documents

Publication Publication Date Title
HUP9700344A2 (en) Substituted quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP9902850A3 (en) Quinazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP9901535A3 (en) Aryl pyrimidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9802565A3 (en) N-benzyl-dioxothiazolidinylmethyl-benzamide derivatives, pharmaceutical compositions containing them and process for producing the same
HUP9602511A2 (en) Aryl-diazinone derivatives, pharmaceutical compositions containing them, and process for producing all these
HUP9802839A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them and process for producing them
HUT76286A (en) Quinoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9802300A3 (en) N-heteroaryl-pyridinesulfonamide derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP0000323A3 (en) N-substituted 2-cyanopyrrolidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9701264A3 (en) Aminoacid derivatives, process for producing them and pharmaceutical compositions containing them
HUP9701265A3 (en) Imidazoline derivatives, process for producing them and pharmaceutical compositions containing them
HUP9901153A3 (en) Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them
HUP9901359A3 (en) Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
HUP9603433A3 (en) 4-6-diaryl-pyrimidine-derivatives, process for producing them and pharmaceutical compositions containing them
HUP9600071A3 (en) Indolo-piperidine derivatives, pharmaceutical compositions containing them, process for producing them and their use
HUP9901739A3 (en) Aminoisoquinolines and aminothienopyridine derivatives, process for producing thereof and pharmaceutical compositions containing them
HUP9602681A1 (en) Hydroxy-pyridinone derivatives, process for producing them and pharmaceutical compositions containing them
HUP9600876A3 (en) Benzonitril- and -fluoride derivatives, pharmaceutical compositions containing them, process for producing them and their use
HU9800781D0 (en) Propanolamine derivatives, process for producing them, pharmaceutical compositions containing them and their use
HU9602640D0 (en) Substituted benzoyl-guanidine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9602763A3 (en) 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same
HUT74615A (en) 2,3-cyclic-condensed-1,4-dihydro-pyridine derivatives, process for producing them and pharmaceutical compositions containing the same
HU9501925D0 (en) Ortho-amine-substituted benzoyl-guanidine derivatives, process for producing them their pharmaceutical or diagnostical use, and pharmaceutical compositions containing them
HUP9900105A3 (en) Momopiperazine derivatives, process for producing them and pharmaceutical compositions containing them
HUP9601331A3 (en) Piperazine- and homopiperazine-derivatives, process for producing them and pharmaceutical compositions containing them